Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Enter into a definitive agreement under which Scherer will provide up to $4.5 mil. in financing to Marquest and will guarantee up to an additional $3 mil. for working capital. Marquest will use the $4.5 mil. for capital additions, to pay off short-term credit and for operating expenses. The firms also will work to refinance Marquest's defaulted Swiss bonds, which amount to about $12.6 mil. The definitive deal's terms are different from those of a March 17 revised agreement in principle ("The Gray Sheet" March 22, p. 21). The March pact would have provided $4.5 mil. in financing, as well as $4.5 mil. through a guarantee of proposed mortgage debt. In conjunction with the agreement's transactions, Scherer may acquire up to about 65% of Marquest common stock and will be able to name the majority of Marquest's board members. Scherer also obtains rights to Marquest's ABG blood gas analysis product line, which it will license back to Marquest. Marquest will have a three-year right to repurchase the product line.

You may also be interested in...

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

Generics Approvals Will Decline, US FDA Predicts, But Supplement Work May Grow

With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.

US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak

February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts